TKI-话题@MedSci

#TKI#

128篇内容 | 3905人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1384183, encodeId=a4ef138418315, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=一代TKI浙江医保落地，众专家话非小细胞肺癌精准治疗, objectType=article, longId=124635, objectId=e2f0124635aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2f0124635aa, replyNumber=0, likeNumber=78, createdTime=2017-12-28, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2f0124635aa, moduleTitle=一代TKI浙江医保落地，众专家话非小细胞肺癌精准治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2f0124635aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384182, encodeId=de691384182a5, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=徐兵河教授：泛ErbB受体TKI吡咯替尼具有治疗晚期乳腺癌潜力, objectType=article, longId=123407, objectId=3bce12340e38, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3bce12340e38, replyNumber=0, likeNumber=81, createdTime=2017-12-16, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3bce12340e38, moduleTitle=徐兵河教授：泛ErbB受体TKI吡咯替尼具有治疗晚期乳腺癌潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3bce12340e38)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384181, encodeId=0e5b13841814e, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=阿法替尼（吉泰瑞®）--第二代EGFR-TKI肺癌靶向药物在中国获批, objectType=article, longId=120579, objectId=4e541205e950, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e541205e950, replyNumber=0, likeNumber=64, createdTime=2017-11-19, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e541205e950, moduleTitle=阿法替尼（吉泰瑞®）--第二代EGFR-TKI肺癌靶向药物在中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e541205e950)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384180, encodeId=1e8013841803a, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Blood：CML幼稚细胞通过BMP自分泌环来逃逸TKI治疗。, objectType=article, longId=120265, objectId=9356120265b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9356120265b8, replyNumber=0, likeNumber=71, createdTime=2017-11-17, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9356120265b8, moduleTitle=Blood：CML幼稚细胞通过BMP自分泌环来逃逸TKI治疗。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9356120265b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384179, encodeId=fd9e13841e91a, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=吴一龙教授：TKI药物进入国家医保目录有益于民生, objectType=article, longId=119984, objectId=af94119984bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af94119984bd, replyNumber=0, likeNumber=57, createdTime=2017-11-16, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af94119984bd, moduleTitle=吴一龙教授：TKI药物进入国家医保目录有益于民生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af94119984bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384178, encodeId=f88f13841e8f2, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=陈建华教授：晚期NSCLC一线EGFR-TKI耐药进展后的治疗策略, objectType=article, longId=119408, objectId=f1bc1194081a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1bc1194081a, replyNumber=0, likeNumber=60, createdTime=2017-11-11, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1bc1194081a, moduleTitle=陈建华教授：晚期NSCLC一线EGFR-TKI耐药进展后的治疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1bc1194081a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384177, encodeId=263d13841e77b, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=刘晓晴教授对话张树才教授：三代EGFR-TKI的对比与排兵布阵, objectType=article, longId=119396, objectId=8df0119396d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8df0119396d1, replyNumber=0, likeNumber=76, createdTime=2017-11-11, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8df0119396d1, moduleTitle=刘晓晴教授对话张树才教授：三代EGFR-TKI的对比与排兵布阵, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8df0119396d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384176, encodeId=4abe13841e637, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=[WCLC2017]大咖圆桌会：多学科专家共话肺癌EGFR TKI靶向治疗热点, objectType=article, longId=118378, objectId=d0071183e824, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d0071183e824, replyNumber=0, likeNumber=71, createdTime=2017-11-03, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d0071183e824, moduleTitle=[WCLC2017]大咖圆桌会：多学科专家共话肺癌EGFR TKI靶向治疗热点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d0071183e824)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384175, encodeId=c1e213841e575, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=【WCLC 2017】再添新桂|王洁教授团队BENEFIT研究证实液体活检指导一线TKI疗效的可行性, objectType=article, longId=116749, objectId=41a4116e4987, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41a4116e4987, replyNumber=0, likeNumber=92, createdTime=2017-10-20, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41a4116e4987, moduleTitle=【WCLC 2017】再添新桂|王洁教授团队BENEFIT研究证实液体活检指导一线TKI疗效的可行性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41a4116e4987)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384174, encodeId=e20413841e4c2, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=JCO：IMPRESS研究公布最终OS结果：耐药后EGFR –TKI原药能不能继续使用？, objectType=article, longId=116014, objectId=6fb0116014fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fb0116014fb, replyNumber=0, likeNumber=59, createdTime=2017-10-14, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fb0116014fb, moduleTitle=JCO：IMPRESS研究公布最终OS结果：耐药后EGFR –TKI原药能不能继续使用？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fb0116014fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384173, encodeId=9b3813841e3d0, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=CSCO 2017 莫树锦教授热评肺癌TKI治疗, objectType=article, longId=114655, objectId=d3f011465585, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3f011465585, replyNumber=0, likeNumber=57, createdTime=2017-09-30, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3f011465585, moduleTitle=CSCO 2017 莫树锦教授热评肺癌TKI治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3f011465585)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384172, encodeId=115c13841e292, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=【CSCO看点】中国晚期NSCLC EGFR TKI耐药后T790M 突变率知多少？, objectType=article, longId=114385, objectId=e7721143856c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7721143856c, replyNumber=0, likeNumber=77, createdTime=2017-09-28, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7721143856c, moduleTitle=【CSCO看点】中国晚期NSCLC EGFR TKI耐药后T790M 突变率知多少？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7721143856c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384171, encodeId=79bf13841e12f, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Eur Respir J：EGFR-wt晚期非小细胞肺癌：EGFR-TKIs疗效不如化疗？, objectType=article, longId=114074, objectId=7e4c1140e4f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e4c1140e4f6, replyNumber=0, likeNumber=91, createdTime=2017-09-26, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e4c1140e4f6, moduleTitle=Eur Respir J：EGFR-wt晚期非小细胞肺癌：EGFR-TKIs疗效不如化疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e4c1140e4f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384170, encodeId=e72e13841e0ba, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Eur Respir J：EGFR野生型进展性非小细胞肺癌：TKI vs化疗, objectType=article, longId=111675, objectId=74ad1116e521, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=74ad1116e521, replyNumber=0, likeNumber=75, createdTime=2017-09-03, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=74ad1116e521, moduleTitle=Eur Respir J：EGFR野生型进展性非小细胞肺癌：TKI vs化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=74ad1116e521)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384169, encodeId=5a97138416935, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=JCO：抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效, objectType=article, longId=110822, objectId=f90d11082200, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f90d11082200, replyNumber=0, likeNumber=68, createdTime=2017-08-26, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f90d11082200, moduleTitle=JCO：抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f90d11082200)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384168, encodeId=6aed138416877, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=JCO:抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效, objectType=article, longId=110820, objectId=ca66110820db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca66110820db, replyNumber=0, likeNumber=75, createdTime=2017-08-26, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca66110820db, moduleTitle=JCO:抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca66110820db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384167, encodeId=33c8138416ec1, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=T790M突变检测，实现EGFR TKI耐药患者的精准治疗, objectType=article, longId=108175, objectId=29721081e5ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=29721081e5ad, replyNumber=0, likeNumber=80, createdTime=2017-08-10, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=29721081e5ad, moduleTitle=T790M突变检测，实现EGFR TKI耐药患者的精准治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29721081e5ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384166, encodeId=653313841669b, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=EGFR-TKI耐药后的检测标本选择：组织活检vs.液体活检, objectType=article, longId=108173, objectId=b73d1081e30c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b73d1081e30c, replyNumber=0, likeNumber=71, createdTime=2017-08-10, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b73d1081e30c, moduleTitle=EGFR-TKI耐药后的检测标本选择：组织活检vs.液体活检, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b73d1081e30c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384165, encodeId=5a9d13841653c, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Oncotarget：IL-6R抑制剂和TKI的联合治疗或能为肾癌治疗提供一种新型治疗方法, objectType=article, longId=107141, objectId=799310e141c9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=799310e141c9, replyNumber=0, likeNumber=29, createdTime=2017-07-31, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=799310e141c9, moduleTitle=Oncotarget：IL-6R抑制剂和TKI的联合治疗或能为肾癌治疗提供一种新型治疗方法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=799310e141c9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384164, encodeId=d2ff13841644a, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=J Natl Cancer Inst：CML患者可以停止TKI治疗吗？, objectType=article, longId=105937, objectId=0f0410593e49, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f0410593e49, replyNumber=0, likeNumber=67, createdTime=2017-07-20, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f0410593e49, moduleTitle=J Natl Cancer Inst：CML患者可以停止TKI治疗吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f0410593e49)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

TKI

2020-05-29

lsj628 (审核中...)

前往app查看评论内容

#TKI#

一代TKI浙江医保落地，众专家话非小细胞肺癌精准治疗

2017-12-28

lsj628 (审核中...)

前往app查看评论内容

#TKI#

徐兵河教授：泛ErbB受体TKI吡咯替尼具有治疗晚期乳腺癌潜力

2017-12-16

lsj628 (审核中...)

前往app查看评论内容

#TKI#

阿法替尼（吉泰瑞®）--第二代EGFR-TKI肺癌靶向药物在中国获批

2017-11-19

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Blood：CML幼稚细胞通过BMP自分泌环来逃逸TKI治疗。

2017-11-17

lsj628 (审核中...)

前往app查看评论内容

#TKI#

吴一龙教授：TKI药物进入国家医保目录有益于民生

2017-11-16

lsj628 (审核中...)

前往app查看评论内容

#TKI#

陈建华教授：晚期NSCLC一线EGFR-TKI耐药进展后的治疗策略

2017-11-11

lsj628 (审核中...)

前往app查看评论内容

#TKI#

刘晓晴教授对话张树才教授：三代EGFR-TKI的对比与排兵布阵

2017-11-11

lsj628 (审核中...)

前往app查看评论内容

#TKI#

[WCLC2017]大咖圆桌会：多学科专家共话肺癌EGFR TKI靶向治疗热点

2017-11-03

lsj628 (审核中...)

前往app查看评论内容

#TKI#

【WCLC 2017】再添新桂|王洁教授团队BENEFIT研究证实液体活检指导一线TKI疗效的可行性

2017-10-20

lsj628 (审核中...)

前往app查看评论内容

#TKI#

JCO：IMPRESS研究公布最终OS结果：耐药后EGFR –TKI原药能不能继续使用？

2017-10-14

lsj628 (审核中...)

前往app查看评论内容

#TKI#

CSCO 2017 莫树锦教授热评肺癌TKI治疗

2017-09-30

lsj628 (审核中...)

前往app查看评论内容

#TKI#

【CSCO看点】中国晚期NSCLC EGFR TKI耐药后T790M 突变率知多少？

2017-09-28

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Eur Respir J：EGFR-wt晚期非小细胞肺癌：EGFR-TKIs疗效不如化疗？

2017-09-26

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Eur Respir J：EGFR野生型进展性非小细胞肺癌：TKI vs化疗

2017-09-03

lsj628 (审核中...)

前往app查看评论内容

#TKI#

JCO：抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效

2017-08-26

lsj628 (审核中...)

前往app查看评论内容

#TKI#

JCO:抗VEGFR-TKI耐药也不怕，卡博替尼治疗末线分化型甲状腺癌仍有很好的疗效

2017-08-26

lsj628 (审核中...)

前往app查看评论内容

#TKI#

T790M突变检测，实现EGFR TKI耐药患者的精准治疗

2017-08-10

lsj628 (审核中...)

前往app查看评论内容

#TKI#

EGFR-TKI耐药后的检测标本选择：组织活检vs.液体活检

2017-08-10

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Oncotarget：IL-6R抑制剂和TKI的联合治疗或能为肾癌治疗提供一种新型治疗方法

2017-07-31

lsj628 (审核中...)

前往app查看评论内容

#TKI#

J Natl Cancer Inst：CML患者可以停止TKI治疗吗？

2017-07-20

科室
- - 订阅+
  - 更多科室
工具
服务